Novartis Ag

Cytokine Pharmasciences, Inc.

The Picower Institute for Medical Research

Novartis Pharma Gmbh

Pamela Cohen

Terence O'Reilly

Markus Wartmann

Manuel Litchman

Kevin J Tracey

Michael I Bukrinsky

Helena Schmidtmayerova

The invention relates to the treatment of a proliferative disease, especially according to certain treatment regimens, with an epothilone, especially with epothilone A and more preferably epothilone B; as well as to the treatment of certain cancers with such an epothilone.

Cancer treatment with epothilones

There is disclosed a method for treating diseases and disorders involving T cell activation and HIV-infection using the p38 mitogen activated protein kinase (MAPK) signaling pathway as a target for intervention. There is further disclosed a use for guanylhydrazone-substituted compounds to treat diseases and disorders related to T cell activation and HIV-infection.

Guanylhydrazones useful for treating diseases associated with T cell activation

There is disclosed a method for treating diseases and disorders involving T cell activation and HIV-infection, using the p38 mitogen activated protein kinase (MAPK) signaling pathway as a target for intervention. There is further disclosed a use for guanylhydrazone-substituted compounds to treat diseases and disorders related to T cell activation and HIV-infection.

Guanylhydrazones useful for treating diseases associated with T cell

Growing community of inventors

Tenafly, NJ, United States of America

Pamela Cohen